Results for egfr translation from Danish to English

egfr ≥45 til
egfr ≥45 to

20.0 egfr-mutation+
egfr mutation+

egfr-mutation ukendt
egfr mutation

patienter med egfr-forbedring
patients with egfr improvement

egfr aktiverer proteiner kaldet ras.
egfr activates proteins called ras.

canagliflozin bør seponeres ved vedvarende egfr
canagliflozin should be discontinued when egfr is persistently below

egfr er involveret i udviklingen af fosteret.
egfr is involved in foetal development.

status for egfr-mutation og kliniske karakteristika
egfr mutation status and clinical characteristics

egfr har betydning for kræftcellernes vækst og spredning.
egfr is involved in the growth and spread of cancer cells.

erlotinib hæmmer effektivt den intracellulære phosphorylering af egfr.
erlotinib potently inhibits the intracellular phosphorylation of egfr.

egfr udtrykkes på celleoverfladen af normale celler og cancerceller.
egfr is expressed on the cell surface of normal cells and cancer cells.

derudover inducerer necitumumab internalisering og nedbrydning af egfr in vitro.
in addition, necitumumab induces egfr internalization and degradation in vitro.

begge undersøgelser omfattede patienter med og uden egfr-mutation.
both studies included patients with and without the egfr mutation.

egfr-mutation+ egfr-mutation- har aldrig røget
egfr mutation+ egfr mutation- never-smoker ever-smoker adenocarcinoma

den epidermale vækstfaktorreceptor (egfr) er involveret i udviklingen af fosteret.
the epidermal growth factor receptor (egfr) is involved in foetal development.

i prækliniske sårhelingsmodeller har egfr-selektive tyrosinkinasehæmmere imidlertid vist sig at forsinke sårheling.
however, in preclinical wound healing models egfr selective tyrosine kinase inhibitors were shown to retard wound healing.

cetuximab blokerer bindingen af kropsegne egfr-ligander, hvilket hæmmer receptorens funktion.
cetuximab blocks binding of endogenous egfr ligands resulting in inhibition of the function of the receptor.

egfr-mutationer kan føre til vedvarende aktivering af anti-apoptotiske og proliferative signalveje.
egfr mutations may lead to constitutive activation of anti-apoptotic and proliferation signaling pathways.

i ikke-kliniske modeller medfører hæmning af egfr phosphortyrosin cellestase og/eller celledød.
in non-clinical models, inhibition of egfr phosphotyrosine results in cell stasis and/or death.

epidermal growth factor receptor (egfr)-monoklonale antistoffer i kombination med kemoterapi, som indeholder bevacizumab
egfr monoclonal antibodies in combination with bevacizumab chemotherapy regimens